FDA
-
-
-
-
-
-
-
Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity
-
-
-
-
-
-
-
Biophytis: Biophytis Presents Sarconeos (BIO101) Development Program in Sarcopenia at the 12th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) in Boston April 20-22, 2022
-
-
-
-
-
-
-
Biophytis Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase 2/3 COVA Study With Sarconeos (BIO101) in COVID-19
-
-
-
-
-
-
-
Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market
-
-
322,093 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

